Pancreatic cancer remains a challenging disease with an overall cumulative 5-year survival rate around 6%. Though significant progress has been made in the availability of diagnostic techniques and treatment strategies, pancreatic cancer remains a disease of high mortality rate. Therefore, there is an urgent need for a better understanding of the molecular mechanisms that governs the oncogenesis and metastasis process of pancreatic cancer. In the present study, by using the Cancer Genome Atlas (TCGA) dataset analysis, we demonstrated that sorting nexin 6 (SNX6) serves as a biomarker for predicting prognosis of pancreatic cancer. In vitro studies demonstrated that silencing of SNX6 expression reduced cell proliferation, colony formation, invasion, and metastasis. Higher level of SNX6 helps maintain the mesenchymal properties, which renders migration and invasive capacities to pancreatic cancer cells. Moreover, in the process of TGF-β-induced epithelial to mesenchymal transition (EMT), the expression level of SNX6 was increased, and silencing of SNX6 expression could inhibit the TGF-β-induced EMT program. These results collectively uncovered a novel predictive marker for pancreatic cancer and provided the possible underlying molecular mechanism.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) has long been well known as one of the most devastating human malignancies in the world, and has the worst prognosis [1] . Poor response to chemotherapy, extensive invasive ability, and metastatic potential contribute to the poor prognosis of pancreatic cancer [2] . Although certain degree of progress has been made, its current 5-year survival rate is disappointedly around 6%, with no significant change in the past 40 years [3] . Until now, the only curative treatment available for PDAC is surgical resection. However, because of the extensive and malignant biological properties of pancreatic cancer, even after successful surgery, the 5-year survival rate remains within 10%-25% [4] . Considering these extremely poor outcomes, there is an urgent need for a better understanding and elucidation of the molecular and cellular mechanisms involved in the oncogenesis and metastasis of pancreatic cancer.
Recently, it has been shown that the spread of pancreatic cancer cells is prior to or in parallel to the establishment of primary tumor, which provides a potential explanation that at the time of diagnosis, metastasis is present in the majority of patients with pancreatic cancer [5] . Moreover, extensive studies indicated that epithelial to mesenchymal transition (EMT), in which cancer cells lose epithelial characteristics and gain a mesenchymal phenotype, plays a crucial role in the process of the initiation of metastasis for tumor cells. Thus, EMT may be one of the newer fields of investigation that could identify new diagnosis markers, or even novel therapeutic options. During EMT, cancer cells acquire both spindle-like morphology and cell-to-cell dissociation, downregulation of epithelial markers (E-cadherin), upregulation of mesenchymal markers (Ncadherin), and induction of specific transcription factor (ZEB1) [6] . Additionally, a series of growth factors, such as transforming growth factor-β (TGF-β), hepatocyte growth factor (HGF), and fibroblast growth factor (FGF), have been known to trigger the process of EMT [7] . However, how these factors are regulated is not clear up to now.
Sorting nexins (SNXs) are a large family of cytoplasmic and membrane-associated proteins which are involved in both intracellular and extracellular trafficking and are associated with the vital process of protein sorting inside the cell [8] . All SNXs contain a unifying feature, i.e. the presence of a Phox-homology domain (PX), a phospholipid binding structural domain which is responsible for the binding to specific phosphoinositides [9] . The first sorting nexin, SNX1, was identified to interact with multiple receptor tyrosine kinases, including the epidermal growth factor receptor (EGFR), the platelet-derived growth factor receptor-β, the insulin receptor, and the transferrin receptor as well as the long form of the leptin receptor [10] , and multiple receptor serine-threonine kinases [8] . Further investigations indicated that SNX1 plays a significant role in the development and manifestation of human colon cancer through in mitogen-activated protein kinase (MAPK) signaling [11] . SNX6 is another important member of the SNX family which was first identified in 2001 [8] . It is a part of the Retromer complex which mediates retrograde transport of transmembrane proteins from endosomes to the trans-Golgi network (TGN). Previous studies have shown that SNX6 interacts with members of the TGF-β family of receptor serine-threonine kinases, which are largely involved in metastasis [8] . TGF-β signaling is well known to control diverse processes and numerous responses, such as cell proliferation, differentiation, immunity, apoptosis, and migration [12, 13] . However, the contribution of SNX6 to the development and progression of pancreatic cancer has seldom been discussed. We hypothesized that increased SNX6 level in pancreatic cancer results in alterations in receptor signaling in these cells as well as promotion of tumorigenesis. In order to determine the characteristics of SNX6, we carried out immunohistochemical staining of human pancreatic cancers, and found significantly increased SNX6 level in these specimens. Using small hairpin RNA (shRNA) depletion of SNX6 in PANC-1 and MiaPaCa-2 cell lines, we found that decreased SNX6 level led to decreased proliferation, colony formation, invasion, and metastasis. Base on the biological interaction between SNX6 and several members of the TGF-β family of receptor serine-threonine kinases, we sought to uncover the correlation between SNX6 and the procession of EMT and explore the underlying mechanism, which may provide novel predictive and treatment targets for pancreatic cancer.
Materials and Methods

The Cancer Genome Atlas dataset analysis
The Cancer Genome Atlas (TCGA)-PAAD on RNA expression (Level 3) of pancreatic cancer patients in terms of RNA-seq by Expectation-Maximization was downloaded from the Cancer Genomics Brower of the University of California, Santa Cruz (UCSC; https://genome-cancer.ucsc.edu/). A total of 160 primary pancreatic cancer samples from patients with detailed expression data were chosen from the updated TCGA database according to parameters mentioned.
Tissue specimens and immunohistochemistry
The PDAC tissue microarrays used in this study were obtained from 60 patients diagnosed with pancreatic cancer at Fudan University Shanghai Cancer Center (FUSCC). Consent was obtained from all patients and approved by the Institutional Research Ethics Committee of FUSCC. Strict pathologic diagnoses and postoperative follow-ups were performed for all patients. Immunohistochemical staining of paraffin-embedded tissues with antibody against SNX6 was performed and scored to determine the protein expression. Based on staining intensity, the pancreatic tumor specimens were grouped according to the SNX6 expression level as negative, weak, moderate, and strong.
Cell culture
The human pancreatic cancer cell lines PANC-1 and MiaPaCa-2 were obtained from the Cell Bank & Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured according to standard ATCC protocols. In brief, PANC-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). MiaPaCa-2 cells were cultured in DMEM medium, supplemented with 10% FBS and 2.5% horse serum. These cell lines have passed the conventional tests of cell line quality control and have DNA profiling of short tandem repeats that are consistent with those reported by the ATCC.
RNA isolation and quantitative real-time PCR
RNA was isolated using Trizol method according to manufacturer instructions (Invitrogen, Carlsbad, USA). The PrimeScript RT reagent (TaKaRa, Dalian, China) was used for reverse transcription. Expression status of candidate genes and β-actin were determined by quantitative real-time PCR using an ABI 7900HT Real-Time PCR system (Applied Biosystems, Foster City, USA). The reactions were incubated at 95°C for 4 min followed by 40 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 30 s. Relative expression was achieved by comparative CT calculation (2−ΔΔCt method). Each reaction was performed in triplicate. Primer sequences are listed in Table 1 .
Western blot analysis
Cells were washed twice with ice-dole PBS and lysed in RIPA buffer for 10 min. Cell debris was removed by centrifugation at 10,000 g for 20 min at 4°C. Total protein (20 μg) was subject to electrophoresis in denaturing 10% SDS-polyacrylamide gel, and then transferred to a membrane for subsequent blocking and blotting using specific antibodies. Anti-β-actin and anti-SNX6 antibodies were Quantitative real-time PCR assay and western blot analysis confirmed that overexpression of SNX6 could downregulate E-cadherin expression, but increase the expression status of N-cadherin and ZEB1. Data were shown as the mean ± SD. SNX6 predicts poor prognosis and contributes to metastasis of pancreatic cancer cells purchased from Proteintech (Chicago, USA), and anti-E-cadherin, anti-N-cadherin and anti-ZEB1 antibodies were obtained from Cell Signaling Technology (Beverly, USA). All secondary antibodies were purchased from Proteintech. After incubation with primary and secondary antibodies, immunoblots were incubated with an enhanced chemiluminescence detection kit (Millipore) and visualized in a dark room.
Lentivirus production and stable cell line selection
In order to generate shRNA expression constructs against SNX6, pLKO.1 TRC cloning vector (Addgene plasmid: 10878; Cambridge, USA) was employed. The 21-bp targets against SNX6 were 5′-AGTAAAGGATGTAGATGATTT-3′ and 5′-TTTGAGCACGAAC GAACATTT-3′, respectively, according to Sigma-Aldrich's Mission shRNA products information (St Louis, USA). Lentiviral particles were produced by co-transfection of pLKO.1-shSNX6 constructs with psPAX2 and pMD2.G into HEK-293 T cells in a ratio of 4:3:1. Cell lines were obtained by infection of PANC-1 and MiaPaCa-2 cells with lentiviral particles followed by puromycin selection.
Transwell invasion assay
A 24-well Transwell chamber with an 8-μm-pore PET membrane (BD Biosciences, Franklin Lakes, USA) was used to perform the migration and invasion assays. The lower chamber was filled with 700 μl media containing 10% FBS. Approximately 6×10 4 cells in 200 μl medium without serum were seeded in the top chamber for migration assay. The cells were allowed to migrate at 37°C with 5% CO 2 for 24 h. After removal of the non-migrating or non-invading cells, the remaining cells were washed, fixed, and stained with crystal violet. The number of migrating and invading cells was counted in six fields randomly selected at ×100 magnification. Experiments were performed at least in triplicate.
Wound healing assay
A total of 5×10 5 cells were seeded in 6-well tissue culture plates.
After attachment, the cells were maintained in serum free medium for 24 h (grown to confluence to form a monolayer). Scratch wounds were created by scraping confluent cell monolayers with a sterile 200-μl pipette tip. The scraped cells were washed away with PBS. After 24, 48, and 72 h, the wound closure was observed with a phase contrast inverted microscope at ×20 magnifications. The degree of cell spread between groups was compared.
EMT induction
For EMT induction, cells were seeded at a density of 2×10 4 cells/ well in 6-well plate and treated with or without TGF-β (10 or 15 ng/ ml) for 24, 48, and 72 h. After incubation, cell morphology was observed under a light microscope and images were collected for further analysis.
Statistical analysis
Statistical analyses were performed using independent Student's ttest (two-tailed) or one-way analysis of variance (ANOVA) with SPSS software (version 20.0, IBM Corp., Armonk, USA) and GraphPad Prism (version 7, GraphPad Software Inc., Chicago, USA). Logistic regression was used to determine the correlation between SNX6, E-cadherin, N-cadherin, and ZEB1 expression levels and clinicopathologic characteristics in the TCGA cohorts. Data were shown as the mean ± standard deviation (SD). P values of <0.05 were considered to be significantly different. 
Results
SNX6 levels are frequently upregulated in human pancreatic cancer
To test the hypothesis that dysregulated expression of SNX6 plays certain roles in pancreatic cancer overall survival, we firstly assessed the impact of SNX6 expression in TCGA cohorts. As shown in Fig. 1A , patients with higher expressions of SNX6 indicated shorter survival. The clinicopathological characteristics of the patients were listed in Table 2 . In order to further validate the TCGA cohort observations, the impact of SNX6 in pancreatic cancer patients was assessed by immunohistochemistry (IHC) staining. Our results demonstrated that SNX6 exhibited different expression patterns in pancreatic cancer patients and different expression status were scored as negative, weakly positive, modestly positive, and strongly positive (Fig. 1B) . Overall survival analysis indicated that patients with higher levels of SNX6 expression exhibited shorter survival (Fig. 1C) . These results collectively indicated that SNX6 may be a predictive prognostic index for pancreatic cancer.
SNX6 regulates migration and invasiveness of pancreatic cancer cells
In order to further assess the function of SNX6 in pancreatic cancer, we then constructed PANC-1 and MiaPaCa-2 cell lines that both stably expressing shRNAs against SNX6, and the silencing effect was validated by using real-time PCR and western blot analysis ( Fig. 2A,  B) . Due to invasion and metastasis are considered as important biological characteristics of malignant tumors, we further assess whether downregulation of SNX6 seriously affects these characteristics of pancreatic cancer. Our results showed that SNX6 knockdown remarkably inhibited the invasiveness of PANC-1 and MiaPaCa-2 cells in the Transwell assay (Fig. 2C,D) . In an alternative wound healing assay, SNX6-depleted cells migrated more rapidly to close the wound than SNX6-intact cells did (Fig. 2E,F) . Furthermore, we also assessed the impact of SNX6 on proliferation of pancreatic cancer cells, and our CCK8 proliferation assay and colony formation assay results demonstrated that SNX6 could also regulate cell proliferation in PANC-1 and MiaPaCa-2 cells (Supplementary Fig. S1 ). Together, these results suggest that SNX6 plays a critical role in the maintenance of biological function of pancreatic cancer cells.
SNX6 regulates the expression of EMT markers in pancreatic cancer cells
As shown in Fig. 3A , silencing of SNX6 could induce morphological changes of PANC-1 and MiaPaCa-2 cells from mesenchymal state to epithelial state. Since EMT has long been known to play a vital role in cell differentiation during development and tumor invasion, and based on the connection between the expression levels of SNX6 and the invasion capacity of pancreatic cancer in vitro, we compared the expressions of some molecules reported to induce EMT in cancer cells, such as epithelial and mesenchymal markers. Our results demonstrated that silencing of SNX6 significantly increased the expression of E-cadherin and suppressed the expression of Ncadherin and ZEB1 in pancreatic cancer cells. It should be noted that E-cadherin expression was not detected in MiaPaCa-2 cells (Fig. 3B,C) , which was in agreement with previous studies [14] . Moreover, immunoblotting using antibodies against E-cadherin, Ncadherin, and ZEB1 validated the observations in PANC-1 and MiaPaCa-2 cells (Fig. 3D,E) . In order to further confirm the relationship between SNX6 and EMT, we constructed both PANC-1 and MiaPaCa-2 cell lines stably overexpressing SNX6, and the overexpression of SNX6 was validated by using real-time PCR and western blot analysis (Fig. 3F,G) . As shown in Fig. 3H , overexpression of SNX6 could induce morphological changes of these cells from epithelial state to mesenchymal state. Our results demonstrated that overexpression of SNX6 significantly suppressed the expression of E-cadherin and increased the expressions of N-cadherin and ZEB1 in pancreatic cancer cells (Fig. 3I-L ). In conclusion, SNX6 could regulate the expression status of EMT-related markers in pancreatic cancer cells.
Expression of SNX6 is increased in TGF-β-induced EMT process
As observed above, inhibiting SNX6 expression could change the expression status of EMT-related markers. We therefore explored whether the expression of SNX6 is changed in the EMT process. Firstly, PANC-1 and MiaPaCa-2 cells were treated with TGF-β to induce EMT. The morphological changes were observed (Fig. 4A) . Quantitative realtime PCR analysis results demonstrated that in the TGF-β-induced EMT process, the expression of SNX6 was increased significantly (Fig. 4B) . In addition, the protein level of SNX6 was also increased in the EMT process (Fig. 4C) . Collectively, these results indicated that SNX6 might positively regulate EMT in pancreatic cancer cells.
SNX6 is crucial for TGF-β-induced EMT process
Based on the observation that TGF-β promoted the process of EMT, and SNX6 expression was significantly increased in this process, we next investigated whether silencing of SNX6 could inhibit the process of EMT induced by TGF-β. To test this hypothesis, SNX6-silenced PANC-1 and MiaPaCa-2 cells and the control cells were treated with 15 ng/ml TGF-β for 72 h. Real-time PCR analysis demonstrated that silencing of SNX6 expression could inhibit decrease in E-cadherin and attenuate the increase in N-cadherin and ZEB1 at mRNA levels when cells were treated with TGF-β (Fig. 5A,  B) . Furthermore, western blot analysis results supported the observation, indicating that silencing of SNX6 could reverse the protein level changes in E-cadherin, N-cadherin, and ZEB1 induced by TGF-β treatment (Fig. 5C) . Subsequently, we assessed the impact of SNX6 on TGF-β induced invasiveness and migration capacity. As revealed by Transwell assay, silencing of SNX6 expression could inhibit TGF-β-induced increase of invasiveness in PANC-1 and MiaPaCa-2 cells (Fig. 5D,E) . Finally, we measured the impact of SNX6 on TGF-β-induced migration of PANC-1 and MiaPaCa-2 cells. Scratch and would healing assay showed that silencing of SNX6 attenuated the increase in the migration capacity induced by TGF-β (Fig. 5F ). These results demonstrated that SNX6 was crucial for TGF-β-induced EMT process and invasiveness in PANC-1 and MiaPaCa-2 cells.
SNX6 is correlated with emt markers in pancreatic cancer patients
Based on the above in vitro observations, we examined the expression levels of SNX6, E-cadherin, N-cadherin, and ZEB1 in pancreatic cancer patients. Consistent with the in vitro observations, patients with higher expression of SNX6 exhibited higher expressions of N-cadherin and ZEB1, but displayed lower Ecadherin expression (Fig. 6A) . ZEB1 is a master regulator of the EMT process and regulates important genes that initiating EMT, metastasis and progress of cancer cells. Thus, we further explored the correlation between SNX6 with ZEB1 in TCGA included patients, and our results showed that SNX6 was positively and significantly correlated with ZEB1 expression in pancreatic cancer patients, which further confirmed the in vitro observations and cell line studies (Fig. 6B) .
Discussion
In the present study, we demonstrated that SNX6 was critical for the invasion of pancreatic cancer cells. Our work also suggested that the dependence of tumor growth and invasiveness of pancreatic cancer cells on SNX6 were mainly attributed to EMT process that regulated by SNX6. Importantly, we identified that SNX6 regulated the process of EMT via downregulation of key epithelial gene (E-cadherin) and upregulation of mesenchymal genes (N-cadherin) and transcriptional factor (ZEB1). Our data also supported the notion that silencing of SNX6 inhibited TGF-β-induced invasion capacity and EMT progress. These findings suggest that higher levels of SNX6 help maintain the mesenchymal properties and induction of EMT progression by TGF-β, which is related to tumorigenesis and metastasis of pancreatic cancer cells. SNX6 has been shown to display negative roles in breast cancer metastasis [15] . Distinct from this cellular function of SNX6 in breast cancer, our in vitro cellular experiments in this study demonstrated that SNX6 knockdown inhibited the proliferation, colony formation, and invasiveness of pancreatic cancer cells. Several activating mutations and genomic aberrations of signaling pathway members (such as KRAS) are related to tumorigenesis and commonly promote EMT [16, 17] . However, the role of SNX in regulating the EMT signaling pathway has not been well described. Intriguingly, the present results indicated that dysregulation of SNX6 expression significantly influenced the process of EMT in pancreatic cancer cells. Consistent with this, we showed that, based on the analysis of TCGA databases, there was a strong correlation between SNX6 and epithelial and mesenchymal markers of EMT in pancreatic cancer patients. In addition, our IHC analysis of pancreatic cancer samples demonstrated that high SNX6 level is associated with poor prognosis. Thus, our findings revealed a previously unidentified mechanism in which SNX6 is required and promotes pancreatic cancer cell growth and metastasis.
EMT is activated in a wide variety of cancer cells, which helps their dissociation from the primary tumor bulk and their intravasation into blood vessels [18] . Despite a vast body of studies regarding the exact roles of EMT in cancers [19] , its applicability in cancer diagnosis and treatment remains limited, due in part to the intrinsic heterogeneity of tumor cells and tumor microenvironment. Studies in the past decade have fueled the interest in EMT in the cancer field, nevertheless, the role of EMT in pancreatic cancer progression and patients' survival is still far from fully understood. Among the markers of EMT, E-cadherin is the most commonly used marker for the epithelial trait and N-cadherin has the mesenchymal properties [19] . As EMT progresses, the expression of E-cadherin is transcriptionally repressed, which stabilizes the loss of epithelial junctions [20] [21] [22] . Specifically, the decreased expression of E-cadherin is balanced by the increased expression of N-cadherin, which results in a 'cadherin switch' that alters cell adhesion [23] . In this study, we revealed that the expressions of epithelial and mesenchymal markers were significantly affected by silencing of SNX6, which then led to the repression of pancreatic cancer cell proliferation and invasion. Some transcription factors, such as ZEB1, were identified as master regulators of gene expression that contributed to the repression of the epithelial phenotype and activation of the mesenchymal phenotype [24, 25] . So, we also tested the expression levels of these transcription factors in SNX6-silenced pancreatic cancer cells. Consistent with our hypothesis, SNX6 expression is positively regulated and correlated with ZEB1 expression in pancreatic cancer cells, but the underlying molecular mechanism needs to be further investigated.
TGF-β is well known to induce EMT in wound healing, fibrosis and cancer [26] [27] [28] [29] . In carcinomas, upregulation and activation of TGF-β promote the response of epithelial plasticity which may further progress to EMT, a pre-requisite for cancer cell dissemination [19] . Consistent with this, our study showed that exogenous TGF-β promoted the progression of EMT in PANC-1 and MiaPaCa-2 cells. Although the function of the SNX6 is not yet clear, its strong interaction with TGF-β receptors suggests that, as a part of its roles in the cell, SNX6 is involved in the targeting of receptors to intracellular trafficking pathways [8] . As SNX6 interacts with members of the TGF-β family of receptor serine-threonine kinases, we hypothesize that SNX6 is related to the TGF-β signaling transduction. To further explore the mechanism of SNX6-EMT axis in pancreatic cancer cells, pharmacological treatment with TGF-β was performed in SNX6-silenced pancreatic cancer cells. Results showed that SNX6 silencing distinctly induced epithelial characteristics, counteracted TGF-β-induced mesenchymal characteristics, and inhibited migration and invasion capacity that drives tumor progression.
In summary, we demonstrated that SNX6 expression was elevated in pancreatic cancer patients, and higher levels of SNX6 indicated worse prognosis. In vitro mechanistic studies revealed that SNX6 was important for maintaining EMT process, which was critical for metastasis and poor prognosis of pancreatic cancer patients (Fig. 6C) . Taken together, the present study uncovered novel molecular markers for the prognosis and treatment of pancreatic cancer.
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